The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.
Ghazaleh Tabatabai
Honoraria - MSD
Wolfgang Wick
Consultant or Advisory Role - Magforce; MSD; Roche
Honoraria - MSD; Roche
Research Funding - Boehringer Ingelheim; MSD; Roche
Joachim Peter Steinbach
Consultant or Advisory Role - Mundipharma; Roche
Honoraria - Medac; Roche
Research Funding - Merck
Antje Wick
No relevant relationships to disclose
Oliver Schnell
No relevant relationships to disclose
Peter Hau
No relevant relationships to disclose
Ulrich Herrlinger
Honoraria - Medac; Roche
Research Funding - Medac; Roche
Michael Sabel
No relevant relationships to disclose
Hans-Georg Wirsching
No relevant relationships to disclose
Ralf Ketter
No relevant relationships to disclose
Oliver Baehr
No relevant relationships to disclose
Michael Platten
No relevant relationships to disclose
Joerg Tonn
Consultant or Advisory Role - Merck Serono; Roche
Honoraria - Merck Serono; Roche
Johannes Huesing
No relevant relationships to disclose
Guido Reifenberger
Consultant or Advisory Role - Merck Serono; Roche
Honoraria - Merck Serono; Roche
Research Funding - Roche
Michael Weller
Honoraria - MSD
Research Funding - MSD